Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model
NEW YORK (
) is trading at unusually high volume Thursday with 789,860 shares changing hands. It is currently at two times its average daily volume and trading up $3.19 (+3.8%) at $87.46 as of 3:51 p.m. ET.
- EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.
Idexx has a market cap of $4.72 billion and is part of the health care sector and drugs industry. Shares are down 6.6% year to date as of the close of trading on Wednesday.
IDEXX Laboratories, Inc. develops, manufactures, and distributes various products and services for the companion animal veterinary, livestock and poultry, water testing, and dairy markets worldwide. The company has a P/E ratio of 26.6, above the S&P 500 P/E ratio of 17.7.
TheStreet Ratings rates Idexx as a
. The company's strengths can be seen in multiple areas, such as its revenue growth, growth in earnings per share, increase in net income, good cash flow from operations and expanding profit margins. We feel these strengths outweigh the fact that the company has had lackluster performance in the stock itself. You can view the full
See all heavy volume stocks in our
or get investment ideas from our
Exclusive Offer: Jim Cramer's 'go-to' small/mid-cap guru Bryan Ashenberg only buys stocks he thinks could return 50-100% See his top picks for 14-days FREE